Hollie Touchet
Internal Medicine · Lafayette, LANPI 1598305260
Payments from drug & device makers
Across 258 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$715
- AstraZeneca$508
- Lilly USA, LLC$498
- Amgen$431
- Pfizer$246
- Bayer$181
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,805100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $715 |
| AstraZeneca | 30 | $508 |
| Lilly USA, LLC | 38 | $498 |
| Amgen | 33 | $431 |
| Pfizer | 14 | $246 |
| Bayer | 12 | $181 |
| Boehringer Ingelheim | 9 | $148 |
| AbbVie | 9 | $144 |
| Otsuka America Pharmaceutical, Inc. | 7 | $126 |
| Novartis | 5 | $78 |
| GSK | 4 | $71 |
| Seqirus USA Inc | 3 | $55 |
| Exact Sciences | 3 | $49 |
| Astellas Pharma US Inc | 3 | $49 |
| Dexcom, Inc. | 3 | $48 |
| Merck | 3 | $47 |
| Edwards Lifesciences | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 7 | $42 |
| Ardelyx, Inc. | 2 | $40 |
| Biogen | 2 | $40 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Shield Therapeutics Inc | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $19 |
| Convatec Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$3,819 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 17 | $21,335 |
| Lagevrio (Eua)Molnupiravir | 12 | $7,623 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,073 |
| Doxycycline Monohydrate | 146 | $1,161 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $856 |
| Cefdinir | 73 | $835 |
| Cephalexin | 52 | $736 |
| Pantoprazole Sodium | 22 | $586 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 88 | $569 |
| Azelastine Hcl | 20 | $550 |
| Ipratropium Bromide | 18 | $482 |
| Losartan Potassium | 19 | $402 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 40 | $387 |
| Ofloxacin | 12 | $348 |
| Fluticasone Propionate | 27 | $346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $498 | $21,33517 claims |
| MerckLagevrio (Eua) | $47 | $7,62312 claims |
| GSKTrelegy Ellipta | $71 | $7,07311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lafayette
- Bryan LebeanLafayette$53K
- Nethuja SalagundlaLafayette$32K
- Himani Reddy ManthenaLafayette$28K
- Hector RoblesLafayette$19K
- Brad BroussardLafayette$17K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.